Author

Ling Jin

Mayo Clinic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Ann L. ObergiD· 2 shared Jamie Nadine Bakkum-GameziD· 2 shared Jamison L. VanBlaricom· 2 shared John Weroha· 2 shared Prabhu ThirusanguiD· 2 shared Scott H. KaufmanniD· 2 shared Shruti RaoiD· 2 shared Sun-Hee LeeiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ann L. ObergORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer

Prabhu Thirusangu, Ling Jin, Shruti Rao, Karthik Balakrishnan, Xiaonan Hou, Jamison L. VanBlaricom, Sun-Hee Lee, Ann L. Oberg, John Weroha, Scott H. Kaufmann, Jamie Nadine Bakkum-Gamez, Viji Shridhar

This paper identifies nuclear cathepsin L as a regulator of replication stress in ovarian cancer, showing that its activation creates a therapeutic vulnerability through replication machinery remodeling and DNA repair inhibition.

bioRxiv · Sep 3, 2026 · PreprintCancer Biology

Drug-induced nuclear cathepsin L (nCTSL) defines a targetable DNA damage response axis and PARP inhibitor sensitivity in ovarian cancer

Prabhu Thirusangu, Ling Jin, Shruti Rao, Upasana Ray, Anya Zhao, Julie K. Staub, Xinyan Wu, Xiaonan Hou, Jamison L. VanBlaricom, Syed Mohammed Musheer Aalam, Sun-Hee Lee, Ann L. Oberg, Nagarajan Kannan, John Weroha, Jeremy Chien, , Viji Shridhar

This study identifies nuclear cathepsin L (nCTSL) as a biomarker for PARP inhibitor sensitivity in ovarian cancer and shows that combining clofarabine with PARP inhibitors enhances therapeutic response.

Cell Communication and Signaling · Aug 28, 2026Peer-reviewedCancer Biology